Earlier this year a collaboration effort was established with the NIH to determine the role of microRNAs in HIV viral replication, and their potential to act as novel drug targets for future therapy, and with the purchase of Parkway Clinical Labs this year, there’s a lot going on here.

Stay tuned as next week I’ll have an interview posted with a discussion with one of the key members of the Rosetta team.  BD 

The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

miRview meso differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung, the company said.

Rosetta Genomics expects to perform approximately 2,000 tests during 2009 in its laboratory in Philadelphia, Pennsylvania.

Rosetta Genomics introduces new cancer test - Pharmaceutical Business Review


Post a Comment

Google Analytics Alternative